L'Agence nationale de la recherche Des projets pour la science

Investissements d'avenirProjets financés


Initiative for the creation of a Vaccine Research Institute (VRI)


Action : Laboratoires d'excellence


N° de convention : 10-LABX-0077

Informations générales

  • Référence projet : 10-LABX-0077
  • RST : Yves LEVY
  • Etablissement Coordinateur : Université de Paris XII (Val de Marne - Paris Est Créteil)
  • Région du projet : Île-de-France
  • Discipline : 5 - Bio Med
  • Aide allouée : 7 000 000 €
  • Date de début du projet : 13/04/2011
  • Date de fin du projet : 12/12/2019
  • Site web du projet : www.vaccine-research-institute.fr
  • Mots clés : HIV; AIDS; HCV; prevention; vaccinology; immunology; virology; dendritic cells; non human primate models; systems biology

Résumé du projet

The mission of the VRI is to conduct research to develop an effective vaccine against HIV/AIDS and HCV. The labex is supported by institutional research bodies (Université Paris Est Créteil (UPEC), ANRS, Institut Pasteur (IP), Commissariat à l'Energie Atomique (CEA), Institut National de la Santé et de la Recherche Médicale (Inserm), Université Paris Sud (UPSUD), Sidaction and Baylor Institute of Immunology (Dallas, Texas)) which have joined forces to create the Institute at the site of the Henri Mondor Hospital/UPEC at Créteil.   The VRI is now structured around 17 research teams, a network of national and international thought leading scientists, a clinical network of physicians, core facilities and an innovative immunomonitoring platform. Through cutting-edge equipment and technologies, the platform, based in Henri Mondor Hospital, will be the key to the development of solid expertise in bio-markers of the vaccine response.   The VRI's structure strengthens the links between basic, translational research, patients associations and the socio-economic world, accelerating vaccine development.   The Labex is also supported from additional institutional (COMUE Paris Est, Conseil, Général du Val de Marne, City of Créteil), industrial (Roche, Sanofi-Aventis, Fit Biotech, Transgene, Antitope, Bachem, Baccinex, Charles River, ABL), international (EC, Bill and Melinda Gates Foundation) and charitable (Sidaction) partners.   A platform of vaccine candidates has been developed including the following candidates: Lipopeptide (LIPO), ex vivo DC; Fusion HIV/anti-DC vaccines, recombinant Pox virus (MVA) or in collaboration: NYVAC (CHUV Lausanne, Eurovacc, Sanofi Pasteur), DNA multi GTU (GTU-MultiHIV B from Fit Biotech), new flavivirus (Replivax vector from Sanofi Pasteur) as well as adjuvant or immunomodulators: Poly ICLC (Oncovir), GLA (IDRI), IL-7 (Cytheris, Revimmune). All these products are currently developed either in preclinical models (NHP) or in phase I or II clinical trials.

(L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.)